Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 814 participants.

Also called NCT04892511

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 814 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04892511
Other papers using this trial's data
  • Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke: A Randomized Clinical Trial JAMA neurology, 2026-08-01 DOI, PubMed 42258192, PMC13247842 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04892511. Randomized; no masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2024-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke
Acronym
HOPE
Condition
Acute Ischemic Stroke
Intervention (Other)
Adjusted medication
Lead sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (class: other)

Record details

Record id
cardio:ct-nct04892511
Content hash
dcd0cda423879bcb9b5355f0f78e68a012da011550fc096dc508d2a8571852a4